Our Newsletter

Retina Meeting

The American Academy of Ophthalmology annual meeting concludes today. With this issue, we begin to report on the Retina Subspecialty Day, where experts presented the latest in research and treatment. The first sessions were on wet AMD and three of those reports appear here. More wet AMD news will follow, and then the meeting on dry AMD.


LUMINOUS Clinical Trial-Wet

The LUMINOUS Clinical Trial is looking at “real world” results of treating those with wet AMD with Lucentis. Rigid clinical trials get FDA approval, but when thousands of patients are treated in real life, do they get the same result?

read more…


Switching Drugs for Wet AMD

Does it help? If you’re getting Avastin and switch to Lucentis, does it make a difference?

read more…


Sustained Release Drugs for AMD

Could this approach eliminate or lessen the need for eye injections?

read more…


Financial Aid For AMD Injections

The standard treatment is for wet macular degeneration involves repeated injections into the eye.  These can be very expensive, especially for someone without a secondary insurance.  Lucentis and Eylea cost around $2000 per injection.  The financial burden can be overwhelming.

The Patient Access Network (PAN) Foundation is dedicated to providing help and hope to underinsured patients who would otherwise be unable to afford high-cost specialty medications.

read more…